Literature DB >> 28292198

Prospective Analysis of a Complete Retrograde Ureteroscopic Technique with Holmium Laser Stent Cutting for Management of Encrusted Ureteral Stents.

Alexandre Thomas1,2, Jonathan Cloutier1, Luca Villa1, Julien Letendre1, Achilles Ploumidis1, Olivier Traxer1.   

Abstract

Purpose: To propose and evaluate a new endoscopic technique using only a retrograde ureteroscopic approach for the removal of heavily encrusted ureteral stents.
Methods: Data from 51 consecutive patients with encrusted and retained ureteral stents were prospectively collected. Description of the successive steps of surgery is detailed. The holmium yttrium aluminum garnet (Ho:YAG) laser properties offer the opportunity for fragmentation of stent-attached encrustation and the ability to cut the stent itself. Reducing the length of the stent is critical to creating space in the ureter and to allow free access for ureteroscopes or ureteral access sheath placement. The primary outcome of this study was the feasibility and the safety of this retrograde intrarenal approach. Some factors of encrustation and outcomes are also discussed in comparison with lithotripsy, percutaneous, laparoscopic, open surgery, or a combination of these techniques.
Results: The removal of the encrusted stent was possible with only this retrograde technique in 98% of patients. The transection of the encrusted stent with the Ho:YAG laser was useful in 71% of the patients. Mean operative time was 110 minutes and mean hospital stay was 2.33 days. Postoperative complications were mainly nonobstructive pyelonephritis (10%). The most significant predictor of this life-threatening complication was the presence of struvite stones with the encrusted stent (p = 0.018). Contrariwise, operative time, body mass index, gender, and encrustation rate were not associated with postoperative pyelonephritis. Both cystine stone disease and pregnancy led to faster stent encrustation. Conclusions: Retrograde ureteroscopic surgery is efficient and safe for removing retained stents and associated stone burdens. The Ho:YAG laser is essential to perform the encrustation removal and sectioning of the stent.

Entities:  

Keywords:  Double-J stent; encrustation; holmium laser; ureteral stent; ureteroscopy

Year:  2017        PMID: 28292198     DOI: 10.1089/end.2016.0816

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  5 in total

1.  Canadian Urological Association guideline: Management of ureteral calculi - Full-text.

Authors:  Jason Y Lee; Sero Andonian; Naeem Bhojani; Jennifer Bjazevic; Ben H Chew; Shubha De; Hazem Elmansy; Andrea G Lantz-Powers; Kenneth T Pace; Trevor D Schuler; Rajiv K Singal; Peter Wang; Michael Ordon
Journal:  Can Urol Assoc J       Date:  2021-12       Impact factor: 1.862

2.  Removal of an encrusted ureteral stent by cutting the stent with a holmium laser using 4.5-Fr semi-rigid and flexible ureteroscopes.

Authors:  Satoshi Imai; Takaaki Inoue; Mototsugu Muramaki; Yuji Yamada; Masato Fujisawa
Journal:  IJU Case Rep       Date:  2020-08-01

3.  A Novel Telescopic Access Sheath Method to Manage Encrusted or Knotted Retained Ureteral Stents.

Authors:  Dinesh K Agarwal
Journal:  J Endourol       Date:  2022-03-10       Impact factor: 2.619

Review 4.  Endourological management of encrusted ureteral stents: an up-to-date guide and treatment algorithm on behalf of the European Association of Urology Young Academic Urology Urolithiasis Group.

Authors:  Patrick Juliebø-Jones; Amelia Pietropaolo; Mathias Sørstrand Æsøy; Øyvind Ulvik; Christian Beisland; Ewa Bres-Niewada; Bhaskar K Somani
Journal:  Cent European J Urol       Date:  2021-12-06

5.  Post-Ureteroscopy Infections Are Linked to Pre-Operative Stent Dwell Time over Two Months: Outcomes of Three European Endourology Centres.

Authors:  Robert M Geraghty; Amelia Pietropaolo; Luca Villa; John Fitzpatrick; Matthew Shaw; Rajan Veeratterapillay; Alistair Rogers; Eugenio Ventimiglia; Bhaskar K Somani
Journal:  J Clin Med       Date:  2022-01-09       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.